Ameriprise
LENZ

Ameriprise’s LENZ Therapeutics LENZ Stock Holding History

Ameriprise’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-136,896
Closed -$2.19M – 4238
2025
Q4 		$2.19M Buy
136,896
+81,223
+146% +$2.37M ﹤0.01% 2942
2025
Q3 		$2.59M Buy
55,673
+1,730
+3% +$63.6K ﹤0.01% 2871
2025
Q2 		$1.58M Sell
53,943
-12,087
-18% -$329K ﹤0.01% 3073
2025
Q1 		$1.7M Buy
66,030
+17,942
+37% +$442K ﹤0.01% 2980
2024
Q4 		$1.39M Sell
48,088
-16,853
-26% -$514K ﹤0.01% 3094
2024
Q3 		$1.54M Buy
+64,941
New +$1.44M ﹤0.01% 3038

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Ameriprise's LENZ Position: Q1 2026 in Review

Ameriprise sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 136,896 shares — an estimated $2.19M sold.

Ameriprise first reported a position in LENZ in Q3 2024 and held it in 6 quarters. The position peaked at $2.59M in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Ameriprise reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 136,896 LENZ Therapeutics shares in Q1 2026, an estimated $2.19M.
  • Ameriprise first reported a position in LENZ Therapeutics in Q3 2024 and held it in 6 quarters.
  • Ameriprise's LENZ Therapeutics position peaked at $2.59M in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.